Nuvalent Down Over 6%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Why Nuvalent (NUVL) Shares Are Down 6% Today
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting
Reported Earlier, Nuvalent Prices $500M Upsized Public Offering Of 5M Common Share At $100/Share
All Shares Are Being Offered by Nuvalent >NUVL
Nuvalent: Underwriters Have 30-Day Option to Purchase Up to an Additional 750,000 Shares of Class A Shares at Public Offering Price >NUVL
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Top Midday Gainers
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Stocks Making the Biggest Moves Midday: Nuvalent, Alcoa, Sprouts Farmers Market, Apple and More
Nuvalent Up Over 22%, on Track for Record High Close -- Data Talk
Cancer Biotech Nuvalent's Stock Jumps on Positive Data -- Barrons.com
Nuvalent Says 2 Potential Lung Cancer Drugs Show 'Favorable Tolerability'
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Nuvalent Shares Are Trading Higher After the Company Highlighted Results for Its ROS1 and ALK-Positive NSCLC Programs and Accelerated Its Development Timeline. Also, the Company Announced a $350 Million Public Offering and Multiple Firms Raised Their...
Nuvalent Price Target Raised to $132.00/Share From $102.00 by BMO Capital
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $100 to $135
On Sep 16, major Wall Street analysts update their ratings for $Nuvalent(NUVL.US)$, with price targets ranging from $100 to $135.Barclays analyst Peter Lawson maintains with a buy rating, and
Sector Update: Health Care
Nuvalent Is Maintained at Buy by Stifel
Nuvalent Analyst Ratings